parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in hepatic stellate cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	3 Parkinson's papers of 99	0.82
pathways Reactome	4 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 14784

HSPB2 in dopamine neurons, braak-0.62 (p 0.073) → +0.07 (p 0.855)receipt 14791
HSPB2 in astrocytes, braak-0.76 (p 0.017) → -0.19 (p 0.630)receipt 14790

receipt 14791: HSPB2 in dopamine neurons, braak

power: full sample -0.29 (p 0.239, n 18), 95% CI -0.67 to +0.20. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.28 (p 0.265, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.30 (p 0.225, n 18). could be the mix.
skeptic: leave-one-out range -0.39 to -0.20, sign flips 0; without severely affected donors -0.29 (p 0.239, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for HSPB2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 14790: HSPB2 in astrocytes, braak

power: full sample -0.44 (p 0.067, n 18), 95% CI -0.75 to +0.03. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.45 (p 0.064, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.40 (p 0.099, n 18). could be the mix.
skeptic: leave-one-out range -0.62 to -0.37, sign flips 0; without severely affected donors -0.44 (p 0.067, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for HSPB2 in astrocytes.

case closed: nothing better to follow up.

loading the receipts